There are 2789 resources available
554P - Phase I clinical trial of OBP-301, a novel telomerase-specific oncolytic virus, in combination with radiotherapy in esophageal cancer patients
Presenter: Shunsuke Tanabe
Session: ePoster Display
555TiP - A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors
Presenter: Emiliano Calvo
Session: ePoster Display
556TiP - A phase I study of SGN-STNV, a novel antibody–drug conjugate targeting sialyl-thomsen-nouveau antigen (STn), in adults with advanced solid tumors (SGNSTNV-001)
Presenter: Nehal Lakhani
Session: ePoster Display
557TiP - SGNTUC-019: Phase II basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations
Presenter: Martin Reck
Session: ePoster Display
558TiP - Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies
Presenter: Vincent Ribrag
Session: ePoster Display
559TiP - A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN inactivating mutations
Presenter: Jordi Rodon
Session: ePoster Display
560TiP - A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations
Presenter: Simon Crabb
Session: ePoster Display
561TiP - A phase I dose-escalation study of ZN-d5, an BCL-2 inhibitor with improved selectivity, in patients with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML)
Presenter: Jan Zaucha
Session: ePoster Display